Literature DB >> 620081

Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.

R J Jacobson, A Salo, P J Fialkow.   

Abstract

The glucose-6-phosphate dehydrogenase (G-6-PD) types and chromosomes of hematopoietic and other tissues were determined in a woman with agnogenic myeloid metaplasia. The patient was heterozygous at the X-linked G-6-PD locus so that both B and A isoenzymes were found in nonhematopoietic cells. In contrast, only one G-6-PD type was found in granulocytes, red cells, and platelets. She also had a distinctive chromosome abnormality in blood cells but not in other tissues. These results indicate that agnogenic myeloid metaplasia is a disorder of a pluripotent stem cell and provide strong evidence that it is of clonal origin. In contrast to blood cells, the patient's cultured marrow "fibroblasts" had normal chromosomes and both B and A G-6-PD types, suggesting that the marrow fibrosis is a secondary abnormality. Thus, at least in this case of agnogenic myeloid metaplasia, the hematopoietic cell proliferation appears to be clonal, and, by inference, possibly neoplastic, whereas the marrow fibrosis is probably not clonal, and therefore appears to be secondary.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620081

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

Review 2.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

3.  Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction.

Authors:  D G Gilliland; K L Blanchard; J Levy; S Perrin; H F Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

Review 4.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

5.  Infiltrative myeloid metaplasia: an unusual cause of gastric outlet obstruction.

Authors:  S M Ismail; K Myers
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

6.  Monoclonal gammopathy in chronic myeloproliferative disorders.

Authors:  T Economopoulos; J Economidou; E Papageorgiou; J Dervenoulas; C Christodoulides; V Pappa; D Karakassis; C Terzoglou; S Athanassiadou; G Chalevelakis
Journal:  Blut       Date:  1989-01

7.  Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia)--correlations between clinical and morphological features.

Authors:  J Thiele; B Hoeppner; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

8.  One thousand patients with primary myelofibrosis: the mayo clinic experience.

Authors:  Ayalew Tefferi; Terra L Lasho; Thitina Jimma; Christy M Finke; Naseema Gangat; Rakhee Vaidya; Kebede H Begna; Aref Al-Kali; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

9.  Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia.

Authors:  Keisuke Shirai; Yasuhiko Sera; William Bulkeley; Meenal Mehrotra; Omar Moussa; Amanda C LaRue; Dennis K Watson; Robert K Stuart; John Lazarchick; Makio Ogawa
Journal:  Exp Hematol       Date:  2009-09-26       Impact factor: 3.084

10.  Polycythemia vera. Further in vitro studies of hematopoietic regulation.

Authors:  J W Adamson; J W Singer; P Catalano; S Murphy; N Lin; L Steinmann; C Ernst; P J Fialkow
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.